Yijiao Xu

Yijiao Xu

Auto-generated profile, based on publicly available information

Yijiao Xu

Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
JLJianying Liu
Jianying Liu
JLJiaxin Liu
Jiaxin Liu
HCHaiyan Chen
Haiyan Chen
QZQingwei Zhang
Qingwei Zhang
PZPeihong Zhang
Peihong Zhang
YXYijiao Xu
Yijiao Xu
Background In the treatment of non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have markedly improved patient survival, yet some patients do not benefit. The existing prognostic factors are limited, highlighting the development of reliable and convenient predictive indicators. Methods A retrospective analysis was performed on 219 NSCLC patients treated with ICIs from June 2019 to January 2024. The nutritional risk screening (NRS 2002) and the neutrophil-to-lymphocyte ratio (NLR) were employed to evaluate the patients' nutritional status and inflammatory response, aiming to investigate the correlation between these markers and treatment outcomes. Results The median follow-up duration for the overall population was 29 (IQR: 25.96–32.04) months. The analysis showed that the median progression-free survival (mPFS) and median overall survival (mOS) in the high nutritional risk group (NRS2002 ≥ 3, accounting for 23.74%) were significantly lower than those in the low nutritional risk group (NRS2002 < 3, accounting for 76.26%) (mPFS: 2.5 vs 16 months; mOS: 8 vs 16 months, both P < 0.001). Similarly, patients with high NLR values (> 4.92) had significantly shorter OS and PFS than those with low NLR (≤ 4.92) values (mOS: 7 vs 18 months; mPFS: 3 vs 17 months, both P < 0.001). Multivariate Cox analysis revealed that a high NRS 2002 score (HR = 2.76, 95% CI 1.68–4.54, P < 0.001) and high NLR (HR = 2.77, 95% CI 1.65–4.64, P < 0.001) were independent predictors of poor prognosis. Risk stratification was performed using a combined scoring system of NRS 2002 and NLR (0 points—low risk, 1 point—moderate risk, 2 points—high risk), and it was found that as the risk score increased, OS and PFS significantly decreased (mOS: 8 [2.61–13.39] vs 16 [13.04–18.96] vs NA [NA-NA] months; mPFS: 2.5 [0.99–4.02] vs 8.5 [5.47–11.53] vs 16 [11.41–20.59] months, respectively, both P < 0.001). The utility of the combined NLR and NRS2002 scoring model was assessed using a time-dependent receiver operating characteristic (ROC) curve, with results indicating that at 12 months, the AUC value of the combined scoring model was 0.81 (CI 0.72–0.90). At 24 and 36 months, the AUC values were 0.73 (CI 0.66–0.80) and 0.70 (CI 0.64–0.76), respectively. Moreover, the nomogram model exhibited high predictive accuracy in predicting survival prognosis, with AUC values of 0.84 (CI 0.77–0.91), 0.85 (CI 0.79–0.91), and 0.78 (CI 0.69–0.88) at 12, 24, and 36 months, respectively. Conclusion The combined NRS 2002 and NLR scoring can serve as an effective prognostic tool for NSCLC patients receiving ICIs treatment. This scoring system helps clinicians more accurately identify patients who will benefit from immunotherapy, thereby facilitating more personalized treatment plans. Further validation of this scoring system's applicability and reliability is warranted in future multicenter, large-sample prospective studies.

8 October 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
HCHaiyan Chen
Haiyan Chen
YXYijiao Xu
Yijiao Xu
JLJianying Liu
Jianying Liu
SYShuwen Yang
Shuwen Yang
HJHongni Jiang
Hongni Jiang
ZCZhisheng Chen
Zhisheng Chen
Purpose Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with immune-related adverse events (irAEs). This study analyzes the relationship between irAEs and treatment effectiveness in advanced non-small cell lung cancer (NSCLC) patients. Methods We conducted a retrospective study of NSCLC patients treated with ICIs from March 2019 to October 2022 at Zhongshan Hospital (Xiamen). Patients were divided into irAE and non-irAE groups, and treatment outcomes were compared. Results A total of 154 patients were included, with 36.4% in the irAE group and 63.6% in the non-irAE group. Most irAEs were Grade 1–2 (86.4%), with 13.6% being Grade 3 or higher. The irAE group had higher disease control rates (DCR: 94.6% vs. 76.5%, P = 0.004) and objective response rates (ORR: 42.9% vs. 26.5%, P = 0.037). Median progression-free survival (PFS) was longer in the irAE group (18 vs. 9 months, HR: 0.53, P = 0.001), as was overall survival (OS: 39.5 vs. 16 months, HR: 0.46, P = 0.001). Landmark analysis at 6 and 12 weeks confirmed that irAEs were associated with improved outcomes. Moreover, patients who experienced two or more adverse events during treatment had significantly longer OS compared to those who had only one or no adverse events (41.6 months vs. 34.0 vs. 23.6, P = 0.003). Conclusion Patients with irAEs demonstrated better outcomes, including ORR, DCR, PFS, and OS. Further studies on biomarkers and irAE incidence are warranted to improve lung cancer management.

1 January 2022 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
YXYijiao Xu
Yijiao Xu
XWXiao Wei
Xiao Wei
XLXingjia Li
Xingjia Li
YCYu Chen
Yu Chen
Xiaodong MaoXiaodong Mao
Xiaodong Mao
CLchao liu
chao liu
The toxic heavy metal cadmium has been proven to cause pancreatic dysfunction and lead to the development of DM. However, the underlying mechanisms have not been completely elucidated. Here, we investigated the effects of cadmium on the pancreatic β cell line MIN6 and explored the underlying mechanisms. The Cell Counting Kit-8 (CCK8) assay and flow cytometry were used to determine cell viability and apoptosis in MIN6 cells. The expression levels of signal transducer and activator of transcription 6 (STAT6) were assessed by western blotting. We further assessed the effects of cadmium on the function of pancreatic β cells under high glucose levels using enzyme-linked immunosorbent assay (ELISA) and western blotting. Insulin secretion and expression were decreased by cadmium in MIN6 cells. In addition, cadmium suppressed cell viability and promoted apoptosis of MIN6 cells, downregulated insulin secretion and genesis of MIN6 cells under high glucose conditions, while inhibiting STAT6. Furthermore, after treatment with IL-4, the activator of STAT6, the MIN6 cell viability suppression and apoptosis promotion effect caused by cadmium were blocked. In conclusion, cadmium inhibits pancreatic β cell MIN6 growth by regulating the activation of STAT6. Our findings reveal a new mechanism of cadmium toxicity in pancreatic β cells.

21 April 2025 in Health Science Reports
Verified
Journal Article
Open access
JLJianying Liu
Jianying Liu
JCJinzhan Chen
Jinzhan Chen
CXCongyi Xie
Congyi Xie
HCHaiyan Chen
Haiyan Chen
SYShuwen Yang
Shuwen Yang
YXYijiao Xu
Yijiao Xu
Background and Aims: To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems—Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)—in non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).Methods: We conducted a retrospective analysis of clinical data from 219 NSCLC patients treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University from June 1, 2019 to January 31, 2024. The therapeutic efficacy and predictive capabilities of the scoring systems were assessed using Kaplan–Meier curves, Cox proportional hazards models, time‐dependent ROC curves, and random survival forest models.Results: The median follow‐up was 29 months (IQR: 25.96–32.04), resulting in 93 observed deaths. Both LIPI and GRIm scores correlated with declining overall survival (OS) and progression‐free survival (PFS) as risk levels increased. LIPI demonstrated superior predictive performance at 12, 24, and 36 months (AUC: 0.70, 0.62, 0.61, respectively). Multivariate analysis identified immune‐related adverse events (irAEs) and lactate dehydrogenase (LDH) levels as independent prognostic factors for OS.Conclusion: LIPI serves as an effective prognostic tool for NSCLC patients receiving immunotherapy, outperforming individual inflammatory markers. Additionally, irAEs and LDH levels are significant independent prognostic factors for OS.

30 January 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
JLJianying Liu
Jianying Liu
HXHaimei Xu
Haimei Xu
CHChenchen Huang
Chenchen Huang
XQXiaonan Qiu
Xiaonan Qiu
XLXuefeng Lu
Xuefeng Lu
YXYijiao Xu
Yijiao Xu
Background: Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) carries a high risk of post-discharge recurrence. Whether admission high-density lipoprotein cholesterol (HDL-C) independently predicts recurrence and how its effect varies over time remain unclear. Methods: A multicenter retrospective study was conducted, including consecutive HTG-AP inpatients from three hospitals from January 2020 to March 2025. The primary endpoint was overall post-discharge recurrence; while the secondary endpoints included recurrence within 6 and 12 months. HDL-C, analyzed both as a continuous variable and by tertiles, was evaluated using Cox models with progressive adjustment. Dose–response was examined by restricted cubic splines (RCS). Time-varying effects were assessed with landmark analyses (0–6 and 6–12 months) and an HDL × log(time) interaction. Robustness was tested using inverse probability of treatment weighting (IPTW). Restricted mean time free of recurrence (RMST) quantified absolute differences. Results: A total of 440 patients were enrolled, and the median follow-up duration was 14.0 months. Lower admission HDL-C was associated with a higher recurrence risk. In the fully adjusted model, each 1 mmol/L increase in HDL-C was associated with a 77% lower hazard of overall recurrence (HR 0.23, 95% CI 0.11–0.48; p < 0.001). Compared with the lowest tertile (T1), risks were reduced in T2 (HR 0.42, 95% CI 0.27–0.64) and T3 (HR 0.33, 95% CI 0.19–0.55; p for trend<0.001). RCS showed a clear linear dose–response with risk plateauing at higher HDL-C. Landmark analyses localized the predictive value to the first year: 0–6 months HR 0.045 (95%CI: 0.012–0.171; p < 0.001) and 6–12 months HR 0.176 (95%CI: 0.054–0.568; p = 0.004); no association was observed beyond 12 months ( p = 0.197). RMST within 12 months was 2.2 months shorter in T1 and 0.5 months shorter in T2 versus T3. Findings were consistent after IPTW (0–6 months aHR = 1.76, 95%CI: 1.12–2.77; 6–12 months aHR = 2.27, 95%CI: 1.38–3.73; 12-month aHR = 3.79, 95%CI: 1.92–7.48; overall aHR = 1.80, 95%CI: 1.14–2.83). Conclusion: Low admission HDL-C is an independent predictor of HTG-AP recurrence with a linear risk gradient, and its predictive effect is most pronounced within 12 months after discharge. Given its stability and accessibility, HDL-C can aid early identification of high-risk patients and inform targeted follow-up and prevention strategies.

23 April 2026 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
HCHaiyan Chen
Haiyan Chen
JLJianying Liu
Jianying Liu
QZQingwei Zhang
Qingwei Zhang
YXYijiao Xu
Yijiao Xu
JLJiaxin Liu
Jiaxin Liu
Venous thromboembolism (VTE) is a serious complication in non-small cell lung cancer (NSCLC), potentially exacerbated by immune checkpoint inhibitors (ICIs